Trial Profile
Phase II Clinical Study Combining Trastuzumab With Etoposide in Treatment of HER2-Positive Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Etoposide
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 07 Jul 2010 Planned end date changed from 1 Jan 2013 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 07 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.